Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in -Infected Guinea Pigs.
Vaccines (Basel)
December 2022
Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China.
Article Synopsis
- LTBI (latent tuberculosis infection) is a significant contributor to active tuberculosis cases, highlighting the importance of treating LTBI for TB elimination.
- Vaccinating with the AEC/BC02 subunit vaccine, in conjunction with a 4-week course of isoniazid-rifampin, showed promising results in a guinea pig model by reducing bacterial load and improving pathological conditions.
- The study confirmed that this combination therapy had no drug-resistant bacteria development within the short treatment period, laying the groundwork for future clinical trials of the AEC/BC02 vaccine.
Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month.
Tuberculosis (Edinb)
May 2021
CSIR-Central Drug Research Institute, Lucknow, 226031, India. Electronic address:
We investigated the preclinical efficacy and safety/tolerability of biodegradable polymeric particles containing isoniazid (INH) and rifabutin (RFB) dry powder for inhalation (DPI) as an adjunct to oral first-line therapy. Mice and guinea pigs infected with Mycobacterium tuberculosis H37Rv (Mtb) were treated with ∼80 and ∼300 μg of the DPI, respectively, for 3-4 weeks starting 3, 10, and 30 days post-infection. Adjunct combination therapy eliminated culturable Mtb from the lungs and spleens of all but one of 52 animals that received the DPI.
View Article and Find Full Text PDFAntibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
Front Immunol
March 2021
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
The lengthy and complicated current regimen required to treat drug-susceptible tuberculosis (TB) reflects the ability of (Mtb) to persist in host tissues. The stringent response pathway, governed by the dual (p)ppGpp synthetase/hydrolase, Rel , is a major mechanism underlying Mtb persistence and antibiotic tolerance. In the current study, we addressed the hypothesis that Rel is a "persistence antigen" presented during TB chemotherapy and that enhanced immunity to Rel can enhance the tuberculocidal activity of the first-line anti-TB drug, isoniazid, which has reduced efficacy against Mtb persisters.
View Article and Find Full Text PDFInduction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of .
Autophagy
June 2020
Immunology Division, CSIR-Institute of Microbial Technology, Chandigarh, India.
Article Synopsis
- Scientists are trying to find new ways to fight infections because some germs are becoming resistant to antibiotics.
- They discovered that certain receptors in our immune cells, like CLEC4E and TLR4, help boost our body's defense against these germs.
- By using special treatments that activate these receptors, they saw improved immunity and less bacteria in sick mice and guinea pigs, showing a new way to help our body fight infections.
Isoniazid-loaded chitosan/carbon nanotubes microspheres promote secondary wound healing of bone tuberculosis.
J Biomater Appl
February 2019
1 Department of burn, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Poor blood circulation makes it difficult for antitubercular drugs to achieve effective bactericidal concentration at tuberculose focus. The residual Mycobacterium tuberculosis around surgical wound would multiply, resulting in nonunion or sinus formation. Carbon nanotubes have strong tissue penetration and can cross many kinds of physiological barriers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!